April 13, 2009 |
About a year ago, patients began trooping into the office of UCLA psychiatrist Andrew Leuchter, asking whether an antipsychotic drug called Abilify "might be right for them." Few appeared to be delusional, plagued by hallucinations or suffering fearsome mood swings. Mostly, they were depressed or anxious, and frustrated by the pace of their recovery. Leuchter wondered what was up: Depressed patients didn't usually seek out drugs used to quell psychiatry's most disturbing symptoms.
January 16, 2009 |
Eli Lilly & Co. taught its sales force a catchy slogan to peddle the antipsychotic drug Zyprexa for treating the elderly. Company salespeople told care providers that 5 milligrams of Zyprexa at 5 p.m. -- or "5 at 5" -- would help dementia patients sleep. One problem: Regulators never approved selling the drug for dementia, and federal prosecutors say this type of marketing led to a record $1.42-billion settlement with Lilly announced Thursday.
January 15, 2009 |
A widely used class of antipsychotic drugs that includes bestsellers Zyprexa, Risperdal and Seroquel is just as likely -- perhaps even more likely -- to cause a fatal heart attack as older antipsychotic drugs like haloperidol, researchers reported today. The findings, which run contrary to a long-standing belief, add to a growing drumbeat of criticism about this class of drugs, known as atypical antipsychotics.
October 8, 2008 |
Drug maker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug, Zyprexa, when it announced a $62-million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication. Lilly agreed to pay California, 31 other states and Washington to resolve an investigation into the company's marketing practices.
March 12, 2008 |
The state of Connecticut sued Eli Lilly & Co. on Tuesday, accusing the drug maker of illegally marketing and concealing serious side effects of its top-selling schizophrenia medicine, Zyprexa. Atty. Gen. Richard Blumenthal is seeking to recover "millions of taxpayer and consumer dollars improperly spent on Zyprexa as a result of its illegal marketing, and millions more spent for treatment of serious side effects from Zyprexa," according to a statement. Indianapolis-based Lilly is in a trial in Alaska that began this month in which the state has made similar claims involving the drug.
January 31, 2008 |
Eli Lilly & Co. said Wednesday that it received a subpoena in November from a U.S. grand jury in Pennsylvania seeking documents involving the marketing of the company's bestselling drug, the antipsychotic Zyprexa. The Indianapolis drug maker is cooperating in state and U.S. investigations into its marketing practices, according to a statement from spokeswoman Marni Lemons.